UNITED THERAPEUTICS CorpUTHREarnings & Financial Report
United Therapeutics Corporation is an American biotechnology company that develops pharmaceuticals and technologies related to organ transplantation, including xenotransplantation. Many of the company's products are focused towards lung disease and organ manufacturing. United Therapeutics is co-headquartered in Silver Spring, Maryland and Research Triangle Park, North Carolina, with additional facilities in Magog and Bromont, Quebec; Melbourne and Jacksonville, Florida; Blacksburg, Virginia; ...
UTHR Q4 2025 Key Financial Metrics
売上高
$790.2M
粗利益
$686.8M
営業利益
$356.7M
純利益
$364.3M
粗利益率
86.9%
営業利益率
45.1%
純利益率
46.1%
前年比成長
7.4%
EPS
$7.66
資金フロー
UNITED THERAPEUTICS Corp Q4 2025 Financial Summary
UNITED THERAPEUTICS Corp reported revenue of $790.2M (up 7.4% YoY) for Q4 2025, with a net profit of $364.3M (up 20.9% YoY) (46.1% margin). Cost of goods sold was $103.4M, operating expenses totaled $330.1M.
Key Financial Metrics
| Total Revenue | $790.2M |
|---|---|
| Net Profit | $364.3M |
| Gross Margin | 86.9% |
| Operating Margin | 45.1% |
| Report Period | Q4 2025 |
Revenue Breakdown
UNITED THERAPEUTICS Corp Q4 2025 revenue of $790.2M breaks down across 7 segments, led by Tyvaso DPI at $338.6M (42.8% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Tyvaso DPI | $338.6M | 42.8% |
| Remodulin | $128.0M | 16.2% |
| Nebulized Tyvaso | $125.7M | 15.9% |
| Orenitram | $121.2M | 15.3% |
| Unituxin | $62.3M | 7.9% |
| Adcirca | $7.8M | 1.0% |
| Other | $6.6M | 0.8% |
UNITED THERAPEUTICS Corp Revenue by Segment — Quarterly Trend
UNITED THERAPEUTICS Corp revenue by segment across the last 4 reported quarters, showing how each business line (such as Tyvaso DPI and Remodulin) has evolved quarter over quarter.
| Segment | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|
| Tyvaso DPI | $338.6M | $336.2M | $315.2M | $302.5M |
| Remodulin | $128.0M | $125.9M | $134.7M | $138.2M |
| Nebulized Tyvaso | $125.7M | $141.8M | $154.4M | $163.8M |
| Orenitram | $121.2M | $131.1M | $123.9M | $120.7M |
| Unituxin | $62.3M | $47.9M | $58.4M | $58.2M |
UNITED THERAPEUTICS Corp Annual Revenue by Year
UNITED THERAPEUTICS Corp annual revenue history includes year-by-year totals (for example, 2025 revenue was $3.2B). Click any linked year to see what changed vs the prior 10-K.
UNITED THERAPEUTICS Corp Quarterly Revenue & Net Profit History
UNITED THERAPEUTICS Corp quarterly results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 2025 | $790.2M | +7.4% | $364.3M | 46.1% |
| Q3 2025 | $799.5M | +6.8% | $338.7M | 42.4% |
| Q2 2025 | $798.6M | +11.7% | $309.5M | 38.8% |
| Q1 2025 | $794.4M | +17.2% | $322.2M | 40.6% |
| Q4 2024 | $735.9M | +19.7% | $301.3M | 40.9% |
| Q3 2024 | $748.9M | +22.9% | $309.1M | 41.3% |
| Q2 2024 | $714.9M | +19.8% | $278.1M | 38.9% |
| Q1 2024 | $677.7M | +33.7% | $306.6M | 45.2% |
損益計算書
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| 売上高 | $677.7M | $714.9M | $748.9M | $735.9M | $794.4M | $798.6M | $799.5M | $790.2M |
| 前年比成長 | 33.7% | 19.8% | 22.9% | 19.7% | 17.2% | 11.7% | 6.8% | 7.4% |
貸借対照表
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| 総資産 | $6.50B | $6.72B | $7.12B | $7.36B | $7.74B | $7.91B | $7.35B | $7.88B |
| 総負債 | $1.16B | $1.03B | $1.02B | $920.0M | $936.7M | $734.4M | $760.9M | $783.8M |
| 株主資本 | $5.34B | $5.70B | $6.10B | $6.44B | $6.81B | $7.17B | $6.59B | $7.10B |
キャッシュフロー
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| 営業CF | $376.5M | $232.2M | $377.2M | $341.2M | $461.2M | $191.7M | $562.1M | $346.2M |